Pharmacokinetics of Cefaclor in Patients with End Stage Renal Disease and During Hemodialysis

AUTOR(ES)

Berman, S. J.

RESUMO

A single 1.0-g dose of cefaclor administered to patients with stable end stage renal disease whose creatinine clearances were <5 ml/min produced a mean peak serum concentration of 48.3 ± 19.8 μg/ml. The half-life was 2.3 ± 0.3 h. Hemodialysis shortened the half-life of a similar dose to 1.6 ± 0.3 h. Approximately one-third (340 mg) of the administered drug was recovered in the dialysate. Multiple doses of 500 mg every 6 h between hemodialysis sessions produced effective serum concentrations and no bioassay evidence of drug accumulation.

Documentos Relacionados

• Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
• Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
• Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis
• Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
• Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.